Hyperglycemia Monitoring and AIC Monitoring with PI3K/AKT Pathway Inhibitors: Practical Approaches and Strategies

December 31, 2024

By Virginia Kaklamani, MD, DSc
Claudine Isaacs, MD

Opinion

Video

Panelists discuss the key safety findings from the INAVO120 trial involving the inavolisib combination, highlighting aspects of its safety profile and how it compares with the safety data and clinical experience with other PI3K pathway inhibitors, noting any unique or notable differences.

EP: 1.Precision Pathways: Emerging Targeted Therapies in HR+/HER2- Breast Cancer

EP: 2.INAVO120 Trial Insights and Inavolisib's Emerging Role in the Treatment Armamentarium

EP: 3.Precision Pathways: Targeted Therapies, Mutation-Driven Treatment Strategies

EP: 4.Biomarker Testing Best Practices for Informed Treatment Decision-Making: Med Onc and Nurse Perspectives

EP: 5.Adapting Biomarker Testing Practices as Targeted Therapies Shift to Earlier Lines of Treatment

Now Viewing

EP: 6.Hyperglycemia Monitoring and AIC Monitoring with PI3K/AKT Pathway Inhibitors: Practical Approaches and Strategies

EP: 7.Treatment Decision-Making in PIK3CA-mut HR+/HER2- Breast Cancer: Key Tolerability Considerations

EP: 8.Strategies for Staying Informed and Coordinating Care as New Agents Emerge in HR+/HER2- Breast Cancer

EP: 9.PI3K Inhibitors, Oral SERDs, Combination Therapies, and the Shifting Treatment Landscape

Video content above is prompted by the following:

The INAVO120 trial showed some interesting safety data with the inavolisib combination. Please walk us through the key safety findings.
What aspects of the safety profile stand out to you compared with data and your experience with other PI3K pathway inhibitors?

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!